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Methods and Results: The following countries were considered: Italy, Slovakia, Greece, Israel,
Slovenia, Serbia, the Czech Republic, Poland, Romania, Hungary, Ukraine, and the Russian
Federation. CRT penetration was defined as the number of patients treated with CRT (CRT patients)
divided by the prevalence of patients eligible for CRT. The number of CRT patients was estimated as
the sum of CRT implantations in the last 5 years, the European Heart Rhythm Association (EHRA)
White Book being used as the source. The prevalence of CRT indications was derived from the
literature by applying three epidemiologic models, a synthesis of which indicates that 10% of heart
failure (HF) patients are candidates for CRT. HF prevalence was considered to range from 1% to 2%
of the general population, resulting in an estimated range of prevalence of CRT indication between
1000 and 2000 patients per million inhabitants. Similarly, the annual incidence of CRT indication,
representing the potential target population once CRT has fully penetrated, was estimated as between
100 and 200 individuals per million. The results showed the best CRT penetration in Italy (47–93%),
while in some countries it was less than 5% (Romania, Russian Federation, and Ukraine).
Conclusion: CRT penetration differs markedly among the countries analyzed. The main barriers
are the lack of reimbursement for the procedure and insufficient awareness of guidelines by the
referring physicians.
Ann Noninvasive Electrocardiol 2015;20(1):43–52
heart failure; cardiac resynchronization therapy; prevalence; incidence
Heart failure (HF) is a chronic progressive disease
that results in substantial morbidity, mortality,
and expenditure of health care resources.1,2
Approximately 1–2% of the adult population in
developed countries suffer from HF, with the
prevalence rising to 10% among persons 70 years
of age or older.3 Clinical trials have established that
cardiac resynchronization therapy (CRT) improves
the clinical outcomes of patients with HF, reduced
left ventricular ejection fraction (LVEF) and left
ventricular conduction delays.2 The European
Society of Cardiology (ESC) Guidelines for the
diagnosis and treatment of acute and chronic
HF 20124 provide class I A recommendation for
CRT treatment, with or without an implantable
cardioverter defibrillator (ICD), in patients with
symptomatic HF, sinus rhythm, QRS width 120
ms with left bundle branch block (LBBB) mor-
phology and LVEF 35%. Although there has
been a substantial increase in CRT implantation
rates across Europe, marked differences among
countries remain.5,6 It is therefore likely that
many patients who could potentially benefit from
this therapy do not receive it. Since 2008, the
European Heart Rhythm Association (EHRA) has
published annual reports on CRT implantation
rates in all represented countries.7 However, the
penetration of CRT in comparison with the number
of eligible patients has not been studied in detail.
The aim of the present analysis was to examine
the penetration of CRT (with or without ICD) on
the basis of the prevalence and incidence of CRT
indications in a number of ESC member countries
covering Central, Southern and Eastern Europe and
Israel.
METHODS
The following countries were considered in the
analysis: Italy, Slovakia, Greece, Israel, Slovenia,
Serbia, the Czech Republic, Poland, Romania,
Hungary, Ukraine, and the Russian Federation.
Each country was represented by a cardiologist,
who actively contributed to the project.
CRT penetration was defined as the number of
patients treated with CRT divided by the number of
patients that, on the basis of ESC Guidelines class
I A recommendation, should receive CRT; that
is, the number of patients with a CRT implanted
(CRT patients) in relation to the prevalence of CRT
indications.
Assuming that the mean duration of recent CRT
devices is 5 years,8 the number of CRT patients was
conservatively estimated as the cumulative num-
ber of CRT implantations over 5 years (from 2007 to
2011), including replacements; this approximation
minimizes the number of patients counted twice.
Both CRT-P (without ICD function) and CRT-D
(with ICD function) were considered. The sources
of data used for the analysis were the annual
EHRA White Book reports.9 All implantation rates
were therefore cross-validated by the country
coordinator.
The prevalence of CRT indication was derived
from the literature; for simplicity, this was assumed
to be constant over a period of a few years. This
hypothesis is plausible, in that: (1) in the short
term (5 years), HF prevalence is fairly stable;10 (2)
the ratio between the incidence and prevalence of
CRT indication is roughly 1:10, which is similar to
the ratio between the incidence and prevalence of
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Figure 1. Simplified hypothesis in which prevalence of
CRT indication is constant, since the mortality rate is
compensated by the incidence of new eligible subjects.
HF, as reported below; (3) as the annual mortality
rate in CRT-indicated patients is about 10%,11
it approximately balances the incidence of new
patients eligible for CRT. Figure 1 shows the
simplified hypothesis, in which the prevalence of
CRT indication is constant.
In order to estimate how many HF patients are
indicated for CRT, three models were developed
and compared:
Model 1 (based on a report from the Italian
Network on Congestive Heart Failure published
by Baldasseroni et al.12): patients with Sinus
Rhythm, LBBB, and LVEF<30% represent 10.8%
of HF patients.
Model 2 (based on a paper by Shenkman et al.13):
among patients with HF, those with QRS duration
120 ms and systolic dysfunction defined as
LVEF <45% account for about 14.1%.
Model 3 (based on a report from the National Reg-
istry to Advance Heart Health (ADVANCENT)
published by El-Chami et al.14 and on data
from the EuroHeart Survey15): 28.9% of systolic
(LVEF 40%) HF patients have sinus rhythm
and QRS 120 ms,14 and, since systolic HF
patients represent 36% of all HF patients,15 CRT
indication—defined as LVEF40%, sinus rhythm
and QRS 120 ms—is present in about 10.4% of
HF patients.
The consensus that emerges from the three
models is that about 10% of patients with HF are
indicated for CRT on the basis of current class I A
guidelines.
Thus, considering that 1–2% of the general
population is affected by HF,3 the prevalence of
CRT indication in the general population is about
0.1–0.2%, which means 1000–2000 individuals per
million population. This range can be defined as
the full CRT penetration range.
Finally, calculations were made for the individ-
ual participating countries. The demographics of
each country were taken from The EHRA White
Book.9 The estimated number of CRT patients
in each country was normalized per million
inhabitants, that is, calculated as the sum of the
last 5 years implantation rates, each normalized for
the current country population. For each country,
the number of CRT patients was compared with the
full CRT penetration range, and CRT penetration
was estimated.
In the field of implantable devices, once full
penetration has been reached, that is, all indicated
patients have received implants, the potential
target for the therapy becomes equal to the annual
incidence rate of indication. Thus, the incidence
represents the real number of patients to treat
every year.
The HF incidence values reported in the
literature range from 0.13% to 1.44% in the general
population.3,16–18 For simplicity, we estimated HF
incidence in a range of 0.1–0.2%, as reported
above. Thus, the annual incidence of CRT in-
dication was estimated in a range of 100–200
individuals per million. For each country, the
number of patients who underwent implantation in
the year 2011 (normalized for resident population)
was compared with the range of incidence of CRT
indication.
Provided the prevalence of eligible patients with
HF is completely covered by CRT implants, the
annual CRT implantation rate should fall into that
range. This means that approximately all new pa-
tients indicated for CRT receive the therapy, which
could be regarded as an ideal condition. When the
penetration of CRT is partial, that range represents
a minimum target. Achieving this target means that
all newly eligible subjects, and possibly a portion of
the remaining HF patients, will receive treatment.
RESULTS
Demographic and CRT implantation data in
the various countries from 2007 to 2011 are
shown in Table 1. Absolute and normalized EHRA
White Book implantation data9 are reported. The
last column displays normalized implantation data
validated by the country’s investigator, which were
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Figure 2. Estimate of patients already treated with CRT in each country compared with the possible range of patients
indicated for therapy, both normalized per million population (range depending on the HF prevalence range).
used to estimate CRT penetration. Figure 2 shows
the numbers of patients in whom CRT-P and CRT-
D devices were implanted from 2007 to 2011
in each country. The range of CRT indication
prevalence represents the estimated range of
subjects that should be treated, according to the
guidelines. For comparison between countries,
both data are normalized per million inhabitants.
The estimated CRT penetration in each country is
shown in Figure 3. The range is calculated on the
basis of HF prevalence, which is between 1% and
2% of the general population.
Figure 4 shows the number of patients treated
with CRT in each country from 2007 to 2011,
normalized per million population, compared with
the range of CRT indication incidence; the latter
represents the number of new patients annually
eligible for CRT and is also normalized per
million inhabitants (range depending on the HF
incidence range, estimated at 0.1–0.2% of the
general population).
Italy is the country where CRT has the highest
penetration: from 47% to 93% of patients indicated
already have a device implanted. On the basis
of the simplified model adopted, this means
that, in the coming years, the number of CRT
implantations should reach a value equal to the
CRT indication incidence, which is estimated to be
in the range of 100–200 implantations per million
population.
Israel and the Czech Republic also display a good
degree of therapy penetration, ranging from 34%
to 68% and from 31% to 62%, respectively. If
maintained, the trend in CRT implantations seen
in both countries in recent years will probably lead
to greater penetration of the therapy in the near
future.
CRT penetration is still only partial in Hungary,
where less than one of three indicated patients is
treated. The figures are even lower in Slovakia
and Poland, where only one of four receives the
therapy. As the implantation rate in these countries
is still low, CRT penetration will probably slowly
improve in the near future.
In Slovenia, Greece, and Serbia, more than 80%
of indicated patients are still not treated, and CRT
adoption in recent years has also been very low.
In Romania, the Russian Federation and
Ukraine, CRT penetration is very poor, since less
that 5% of patients that could benefit from the
therapy are currently treated, and implantation
rates are negligible.
The number of CRT-D devices as a percentage
of total CRT implants is seen to have varied year
by year in the different countries, as shown in
Figure 5. In Italy and Israel, the proportion of
CRT-D devices exceeds 80%, and has remained
stable over the last 5 years. Slovakia, Greece, the
Czech Republic, and Poland currently adopt CRT-
D in more than 75% of cases, with the last two
countries showing an increasing trend year by
year. In Slovenia, CRT-D devices are increasing
and currently account for about 60% of all CRT
implants. In the Russian Federation, Hungary,
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Figure 3. Estimated CRT penetration range in each country, represented as a range
depending on the HF prevalence range.
Figure 4. Number of patients treated with CRT in each country from 2007 to 2011, compared with the range of CRT
indication incidence, which represents the number of new patients annually eligible for CRT; both are normalized per
million inhabitants (range depending on the HF incidence range).
Romania, Serbia, and Ukraine, CRT-P devices are
mainly used.
The main barriers to CRT penetration—as
identified by the physicians representing each
country—are summarized in Table 2.
DISCUSSION
In the present study, we estimated the potential
population eligible for CRT on the basis of HF
epidemiology and, for the first time, we evaluated
the penetration of CRT in terms of prevalence and
incidence in different countries.
According to current ESC guidelines, CRT is
fully recognized as having a class I indication,
level of evidence A, for patients with symptomatic
HF, LVEF 35%, sinus rhythm, and cardiac
dyssynchrony, which is currently defined as QRS
duration 120 ms. The potential CRT target has
been estimated by Linde at al.,19 who concluded
that approximately 0.1% of the adult population
should receive a CRT device. This percentage is
consistent with our estimate of CRT indication
prevalence. However, our study is the first to
estimate CRT penetration, defined as the number
of patients with a device already implanted as a
proportion of the eligible population. Furthermore,
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Figure 5. CRT-D devices as a percentage of total CRT implants in each country from 2007 to 2011.
considering that, once CRT has fully penetrated,
the potential target for the therapy is equal
to the annual incidence of CRT indication, we
also estimated the incidence of CRT indication,
defined as the annual number of new patients
eligible for CRT, and compared this with annual
implantation rates. This number is extremely
important since it approximately represents the
annual number of patients that we will be called
to treat in the years to come. Finally, this analysis
showed that, while CRT is universally accepted
as a therapy for HF, there are significant differ-
ences in terms of penetration among the various
countries considered.
FACTORS AFFECTING
DIFFERENCES IN CRT
PENETRATION AND
OPPORTUNITIES TO PROMOTE
CRT ADOPTION
There are many reasons for the disparities in
CRT penetration observed in different countries.
Reimbursement by the national health care system
for CRT device implantation seems to be an
essential requirement for adequate adoption of
the therapy; in countries where the cost of the
procedure is not reimbursed or is only partially
reimbursed, CRT penetration is very low and the
use of CRT-P devices is predominant. The issue of
the cost-effectiveness of CRT has been addressed
in several papers.20,21 CRT-P appears to be a
highly cost-effective addition to medical therapy
in eligible patients, while CRT-D is cost-effective
when life expectancy at the time of implantation
is reasonable. Indeed, CRT has been shown to be
cost-effective even in the ninth decade.21 However,
the problem is that cost-effectiveness analysis is
difficult to transfer from one country to another,
especially when the costs of labor, drugs, and
medical devices vary significantly. Therefore, it
is important to obtain country-specific data, since
such data could convince governments to allocate
health resources differently and/or prompt local
health care insurers to reimburse CRT.
Another important factor in the adequate adop-
tion of CRT is the availability of qualified personnel
and the equipment required for successful im-
plantation (C arm with the possibility of cine-loop
acquisition, etc.). In some countries, the training
of specialists remains a substantial issue. Training
fellowships granted by the EHRA and/or organized
directly by industry may help in this direction.
The adoption of CRT also depends on the
awareness of physicians and patients. It is therefore
of the utmost importance to “educate” referring
physicians and to establish referral pathways.
Campaigns to raise public awareness of CRT are
another important component of this process.
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Table 2. Considerations and Main Barriers to Therapy Adoption in Each Countries
Country Considerations on CRT Adoption and Main Barriers to Therapy Penetration
Italy Early adoption of CRT, currently well penetrated, thanks to: reimbursement covered by the
national health care system, very high number of implanting centers (approximately
350), training activities, good cooperation with referral physicians, and early adoption of
“gray zone” indications, such as atrial fibrillation.
Israel Good penetration of CRT and strict adherence to implantation guidelines, assisted by
recording of patients’ data in the Israeli ICD Registry, which is highly encouraged and
covers almost 100% of high-power device implantations. Lack of specific reimbursement
for high-power device implantation procedures to public hospitals is a disincentive to
investment in personnel, equipment, and more electrophysiology laboratories.
Czech Republic Despite limited financial resources, CRT has good penetration. Insurance companies
control center accreditation for CRT (currently 19, two of which for CRT-P only) and
verify, through specific registries, that every implantation complies with guidelines.
Important role of education and training activities for implanters and clinical
cardiologists and “Hub and spoke” model facilitate good referral of patients.
Hungary The main obstacle to CRT penetration is that reimbursement is limited. To increase CRT
penetration, the country is intentionally favoring the implantation CRT-P over CRT-D
devices.
Slovakia The main barriers to a wider adoption of CRT are limited financial resources and
reimbursement policies. Another obstacle is the low awareness of guidelines among
physicians working in medical departments in general hospitals, and the resulting
insufficient referral to the four centers implanting CRT.
Poland CRT penetration is severely limited by the budget allocated by the government to the
implanting centers.
Slovenia One of the main barriers is the lack of operators, since before 2005 device implantation
was done by surgeons. Other obstacles are limited financial resources and low
awareness of guidelines.
Greece The main barriers to the penetration of CRT are lack of operators and trained personnel,
low awareness of guidelines and, recently, considerable reduction of hospital budgets
and, consequently, the limitation of implantations.
Serbia The economic situation and consequent limited financial resources are the main reasons
for the predominance of CRT-P. The strategy of the national working group for
pacemaker therapy is to increase CRT-P therapy over CRT-D for better penetration.
Awareness of guidelines is good owing to informational and educational campaigns.
Romania The small number of devices provided by the national health care system means that CRT
penetration is negligible. The overwhelming majority of CRT-D devices are paid for by
patients, which also explains the predominance of CRT-P.
Russian Federation CRT penetration is very poor. The main barriers are the lack of reimbursement: devices
allocated by the national health care system are few; as patients often pay for the
procedure personally, they prefer CRT-P for economic reasons.
Ukraine CRT penetration and current implantation rates are negligible. Financial resources allocated
to supplying devices are scant and implanting physicians lack specific competence.
STUDY LIMITATIONS
The main limitation of the present study is that
estimates of CRT penetration and of the prevalence
and incidence of CRT indication are expressed as
a wide range. This is due to the fact that both the
prevalence and the incidence of HF are reported
as wide ranges in epidemiologic studies. Since
the prevalence of HF ranges from 1% to 2%, the
estimated penetration of the therapy ranges from
one percentage value to another which is twice
as high; although this does not affect comparisons
among countries, the accuracy of the estimated
CRT penetration in any single country is low.
Once further epidemiologic studies have better
determined the value of HF prevalence, the present
analysis will be able to provide a more accurate
estimate of CRT penetration.
Another limitation of the present analysis is
that we used rough HF prevalence and incidence
values, which were not adjusted for age. Thus,
comparisons among countries considered the
same range of prevalence and incidence of CRT
indication in all cases. Since HF is highly correlated
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with age,3 the age distribution of the population
will presumably influence the estimated range CRT
indication in terms of prevalence and incidence,
and consequently the estimate of CRT penetration.
For example, 26% of the Italian population is older
than 60 years, while in the Russian Federation the
figure is 18%.22 A further analysis should consider
the epidemiology of HF adjusted for age, in order
to refine estimates of CRT penetration and better
compare different geographic areas.
CONCLUSIONS
CRT penetration differs markedly among the
countries analyzed. The main obstacles to patient
recruitment are cultural and economic; cultural
barriers are related to the awareness, dissemi-
nation, and implementation of guidelines, while
economic barriers are mainly related to the lack
of reimbursement for the procedure in several
countries.
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